Trevi Therapeutics Inc [TRVI] stock prices are down -2.24% to $8.06 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TRVI shares have gain 6.12% over the last week, with a monthly amount glided 7.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Trevi Therapeutics Inc [NASDAQ: TRVI] stock has seen the most recent analyst activity on August 21, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $18. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on July 01, 2025, and set its price target to $25. On May 28, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $21 on the stock. Raymond James upgraded its rating to a Strong Buy and increased its price target to $29 on March 10, 2025. Needham reiterated its recommendation of a Buy and raised its price target to $25 on March 10, 2025. H.C. Wainwright reiterated a Buy rating for this stock on December 12, 2024, and upped its price target to $7.50.
The stock price of Trevi Therapeutics Inc [TRVI] has been fluctuating between $2.36 and $9.92 over the past year. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Trevi Therapeutics Inc [NASDAQ: TRVI] shares were valued at $8.06 at the most recent close of the market. An investor can expect a potential drop of -0.74% based on the average TRVI price forecast.
Analyzing the TRVI fundamentals
Gross Profit Margin for this corporation currently stands at -0.26% with Operating Profit Margin at -352.89%, Pretax Profit Margin comes in at -324.28%, and Net Profit Margin reading is -323.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.41 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Trevi Therapeutics Inc [NASDAQ:TRVI]’s Current Ratio is 22.42. In addition, the Quick Ratio stands at 22.42 and the Cash Ratio stands at 12.67.
Transactions by insiders
Recent insider trading involved Delfini Lisa, Officer, that happened on Aug 27 ’25 when 0.31 million shares were purchased. Chief Scientific Officer, SCIASCIA THOMAS completed a deal on Mar 25 ’25 to sell 2631.0 shares. Meanwhile, President & CEO GOOD JENNIFER L sold 5263.0 shares on Mar 21 ’25.
